183 related articles for article (PubMed ID: 23589684)
1. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.
Abudagga A; Sun SX; Tan H; Solem CT
Int J Chron Obstruct Pulmon Dis; 2013; 8():175-85. PubMed ID: 23589684
[TBL] [Abstract][Full Text] [Related]
2. Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population.
AbuDagga A; Sun SX; Tan H; Solem CT
J Med Econ; 2013; 16(3):421-9. PubMed ID: 23336296
[TBL] [Abstract][Full Text] [Related]
3. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
4. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
5. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
[TBL] [Abstract][Full Text] [Related]
6. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population.
Coutinho AD; Lokhandwala T; Boggs RL; Dalal AA; Landsman-Blumberg PB; Priest J; Stempel DA
Int J Chron Obstruct Pulmon Dis; 2016; 11():1223-31. PubMed ID: 27354781
[TBL] [Abstract][Full Text] [Related]
7. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
Palli SR; Zhou S; Shaikh A; Willey VJ
J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
[No Abstract] [Full Text] [Related]
8. Impact of COPD Exacerbation Frequency on Costs for a Managed Care Population.
Dalal AA; Patel J; D'Souza A; Farrelly E; Nagar S; Shah M
J Manag Care Spec Pharm; 2015 Jul; 21(7):575-83. PubMed ID: 26108382
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Appropriate Pharmacotherapy Management of COPD Exacerbations and Impact on 6-Month Readmission.
Tran M; Xiang P; Rascati KL; Stock EM; Godley PJ; Coleman A; Bogart MR; Stanford RH
J Manag Care Spec Pharm; 2016 Oct; 22(10):1186-93. PubMed ID: 27668567
[TBL] [Abstract][Full Text] [Related]
10. Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.
Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Vekeman F; Gauthier-Loiselle M; Duh MS; Merrigan JF; Schatz M
Ann Am Thorac Soc; 2016 Jul; 13(7):1067-75. PubMed ID: 27070274
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States.
Diette GB; Dalal AA; D'Souza AO; Lunacsek OE; Nagar SP
Int J Chron Obstruct Pulmon Dis; 2015; 10():415-22. PubMed ID: 25759574
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
[TBL] [Abstract][Full Text] [Related]
13. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
14. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.
Fraser A; Poole P
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013343. PubMed ID: 36373977
[TBL] [Abstract][Full Text] [Related]
15. Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population.
Sethi S; Make BJ; Robinson SB; Kumar S; Pollack M; Moretz C; Dreyfus J; Xi A; Powell D; Feigler N
Int J Chron Obstruct Pulmon Dis; 2022; 17():593-608. PubMed ID: 35342290
[TBL] [Abstract][Full Text] [Related]
16. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
[No Abstract] [Full Text] [Related]
17. COPD exacerbation frequency and its association with health care resource utilization and costs.
Dhamane AD; Moretz C; Zhou Y; Burslem K; Saverno K; Jain G; Renda A; Kaila S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2609-18. PubMed ID: 26664109
[TBL] [Abstract][Full Text] [Related]
18. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
Tkacz J; Evans KA; Touchette DR; Portillo E; Strange C; Staresinic A; Feigler N; Patel S; Pollack M
Int J Chron Obstruct Pulmon Dis; 2022; 17():329-342. PubMed ID: 35177901
[TBL] [Abstract][Full Text] [Related]
19. The St. George's Respiratory Questionnaire Definition of Chronic Bronchitis May Be a Better Predictor of COPD Exacerbations Compared With the Classic Definition.
Kim V; Zhao H; Regan E; Han MK; Make BJ; Crapo JD; Jones PW; Curtis JL; Silverman EK; Criner GJ;
Chest; 2019 Oct; 156(4):685-695. PubMed ID: 31047955
[TBL] [Abstract][Full Text] [Related]
20. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
